{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antimitotic+Agent", "query": { "intervention": "Antimitotic Agent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antimitotic+Agent&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T10:43:13.682Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00547261", "title": "Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "SSR97225", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2007-10", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2009-04-17", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00547261" }, { "nct_id": "NCT00970580", "title": "A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "BIIB022 With Paclitaxel and Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2009-10", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2013-09-16", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California • Denver, Colorado", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970580" }, { "nct_id": "NCT02855359", "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse, Large B-Cell, Lymphoma", "Follicular Lymphoma, Grade 3b", "Transformed Lymphoma / DLBCL" ], "interventions": [ { "name": "denintuzumab mafodotin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-08", "completion_date": "2018-05-15", "has_results": true, "last_update_posted_date": "2019-03-11", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02855359" }, { "nct_id": "NCT00367471", "title": "Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2006-12-07", "completion_date": "2019-09-12", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 3, "location_summary": "La Jolla, California • Indianapolis, Indiana • Greensboro, North Carolina", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00367471" }, { "nct_id": "NCT04469530", "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 55, "start_date": "2020-09-16", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 5, "location_summary": "Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469530" }, { "nct_id": "NCT03961698", "title": "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "IPI-549 (eganelisib)", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-12-17", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 24, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961698" }, { "nct_id": "NCT04177108", "title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo for Atezolizumab", "type": "DRUG" }, { "name": "Placebo for Ipatasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2019-11-25", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 31, "location_summary": "Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04177108" }, { "nct_id": "NCT06052839", "title": "Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-10-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052839" }, { "nct_id": "NCT02087176", "title": "A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Previously Treated Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD1775", "type": "DRUG" }, { "name": "AZD1775 Placebo", "type": "DRUG" }, { "name": "Antimitotic Agent", "type": "DRUG" }, { "name": "pegfiligrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2014-03", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-06-14", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02087176" }, { "nct_id": "NCT02834403", "title": "L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Triple Negative Breast Cancer" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Enteric-coated aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2016-11", "completion_date": "2021-01", "has_results": true, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-09-02T10:43:13.682Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834403" } ] }